345 related articles for article (PubMed ID: 32945941)
1. Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center.
Jaime-Pérez JC; Aguilar-Calderón P; Jiménez-Castillo RA; Ramos-Dávila EM; Salazar-Cavazos L; Gómez-Almaguer D
Ann Hematol; 2020 Nov; 99(11):2513-2520. PubMed ID: 32945941
[TBL] [Abstract][Full Text] [Related]
2. Diagnoses, Outcomes, and Chronicity Predictors of Patients with Secondary Immune Thrombocytopenia: Ten-Year Data from a Hematology Referral Center.
Jaime-Pérez JC; Ramos-Dávila EM; Aguilar-Calderón P; Jiménez-Castillo RA; Gómez-Almaguer D
Rev Invest Clin; 2020 Oct; 73(1):031-038. PubMed ID: 33084609
[TBL] [Abstract][Full Text] [Related]
3. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
[No Abstract] [Full Text] [Related]
6. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia.
Gómez-Almaguer D; Colunga-Pedraza PR; Gómez-De León A; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Jaime-Pérez JC
Br J Haematol; 2019 Jan; 184(2):288-290. PubMed ID: 29270980
[No Abstract] [Full Text] [Related]
9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
10. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.
Gómez-Almaguer D; Herrera-Rojas MA; Jaime-Pérez JC; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Hernández-Reyes J; Ruiz-Arguelles GJ
Blood; 2014 Jun; 123(25):3906-8. PubMed ID: 24802773
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
Vlachaki E; Sousos N; Perifanis V; Kaiafa G; Onoufriadis I; Hatzitolios A; Boura P
Acta Haematol; 2015; 133(1):78-82. PubMed ID: 25170628
[TBL] [Abstract][Full Text] [Related]
13. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Gao Y; Gong M; Zhang C; Kong X; Ma Y
Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.
Watts RG
Clin Pediatr (Phila); 2004 Oct; 43(8):691-702. PubMed ID: 15494875
[TBL] [Abstract][Full Text] [Related]
16. Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing Therapy.
Lai CY; Pettit T
J Pediatr Hematol Oncol; 2019 Nov; 41(8):620-623. PubMed ID: 29889804
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Depré F; Aboud N; Mayer B; Salama A
PLoS One; 2018; 13(6):e0198184. PubMed ID: 29856800
[TBL] [Abstract][Full Text] [Related]
18. An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center.
Fu L; Ma J; Gu H; Ma J; Wei Y; Chen Z; Wu R
Pediatr Blood Cancer; 2021 Jun; 68(6):e29006. PubMed ID: 33720524
[TBL] [Abstract][Full Text] [Related]
19. [Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
Kashiwagi H; Tomiyama Y
Rinsho Ketsueki; 2014 Oct; 55(10):2087-94. PubMed ID: 25297775
[No Abstract] [Full Text] [Related]
20. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
